Directorate Change

RNS Number : 1967K

Induction Healthcare Group PLC

04 May 2022

 

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

Directorate Change

Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, announces that Dr Hugo Stephenson, who is based in Australia, will stand down from his position as Group Executive Director, after seeing priority ambitions for the Group realised during the period of pandemic restrictions, and return to the Non-executive Director role he originally held on admission to AIM in May 2019.

The Board change is a natural evolution of the leadership structure in response to the strong trading position of the Group at close of FY22, and the opportunities for face-to-face interaction which are now possible for the UK based Executive and Senior Management Team as borders re-open. It follows the completion of the integration of the Attend Anywhere acquisition - where most of the team was based in Australia - and the most recently announced successful renewals of Induction Attend Anywhere across NHS England. Both of these played a part in the positive post-period end trading update of 21 April 2022 .

The Company has a dynamic UK based Executive Team in James Balmain (CEO) and Guy Mitchell (CFO), who was appointed in November 2021 . James and Guy are supported by a strong Senior Management Team,  including Dave Williams, who joined as Chief Technology Officer in September 2021 .

Hugo Stephenson commented:   "James and his team have delivered a really strong end to FY22, providing an exemplary outcome for Attend Anywhere contract renewals, generating substantial demand for Zesty as the NHS emerges from pandemic pressures, and establishing a coordinated, global product and technology organisation that is already demonstrating increased delivery capability and cross-product efficiency under Dave Williams' leadership.

From the outset I have imagined Induction Healthcare as an enabler for flexible care around the world allowing healthcare systems to offer patients and providers a range of digital and in-person care options beyond the resource constrained 'bricks and mortar' models historically available through hospitals. I stepped into an executive role at the beginning of the pandemic - from a locked-down basement in Australia - to provide Induction with stability at a time of great global uncertainty and then a physical link with the Attend Anywhere team post acquisition. My heart remains in inspiring Induction to scale worldwide following the impact we are already making in the UK. I am looking forward to focussing on this mission which I can now do much more efficiently and effectively from a non-executive position on our Board."

Induction CEO, James Balmain, said:  "We are indebted to Hugo for his immense contribution to the business since the commencement of the pandemic during a period of uncertainty, changing rules, opportunities and challenges. As we evolve and expand internationally, I'm delighted that Induction will continue to benefit from his experience and expertise. We all are incredibly excited about the future prospects for the business."

- ENDS-

ENQUIRIES

Induction James Balmain, Chief Executive Officer		Via Walbrook PR Ltd: [e-mail]
Guy Mitchell, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)		[phone]
Philip Davies / Kailey Aliyar
Walbrook PR Ltd	[phone] or [e-mail]
Paul McManus / Alice Woodings		Mob: [phone]

About Induction -   www.inductionhealthcare.com

Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access . Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.  

 

END

 

 

BOAUPUUGAUPPPUW